Session

IL-23: Many but different? (Posters)

GUSELKUMAB, AN IL-23P19 SUBUNIT–SPECIFIC MONOCLONAL ANTIBODY, BINDS CD64 ON THE SURFACE OF IL-23-SECRETING MYELOID CELLS, CAPTURES LOCALLY PRODUCED IL-23, AND DELIVERS IL-23 TO INTRACELLULAR COMPARTMENTS
GUSELKUMAB, AN IL-23P19 SUBUNIT–SPECIFIC MONOCLONAL ANTIBODY, BINDS CD64 ON THE SURFACE OF IL-23-SECRETING MYELOID CELLS, CAPTURES LOCALLY PRODUCED IL-23, AND DELIVERS IL-23 TO INTRACELLULAR COMPARTMENTS

IL-23: Many but different? (Posters)  et al.

SHOULD ALL PATIENTS WITH NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASES BE SCREENED FOR METABOLIC BONE DISEASE? RESULTS FROM A DANISH POPULATION-BASED INCEPTION COHORT STUDY
SHOULD ALL PATIENTS WITH NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASES BE SCREENED FOR METABOLIC BONE DISEASE? RESULTS FROM A DANISH POPULATION-BASED INCEPTION COHORT STUDY

IL-23: Many but different? (Posters)  et al.

AZD7798: A NEW CCR9 DEPLETING ANTIBODY TO TREAT CROHN’S DISEASE
AZD7798: A NEW CCR9 DEPLETING ANTIBODY TO TREAT CROHN’S DISEASE

IL-23: Many but different? (Posters)  et al.

EARLY SYMPTOMATIC IMPROVEMENT WITH GUSELKUMAB INDUCTION TREATMENT IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
EARLY SYMPTOMATIC IMPROVEMENT WITH GUSELKUMAB INDUCTION TREATMENT IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY

IL-23: Many but different? (Posters)  et al.

PHARMACOKINETICS, EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PAEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY
PHARMACOKINETICS, EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PAEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY

IL-23: Many but different? (Posters)  et al.

EFFECT OF 104 WEEKS OF MIRIKIZUMAB TREATMENT ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
EFFECT OF 104 WEEKS OF MIRIKIZUMAB TREATMENT ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

IL-23: Many but different? (Posters)  et al.

EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHN’S DISEASE: 104-WEEK EXTENSION RESULTS FROM A PHASE 2 RANDOMIZED CONTROLLED TRIAL
EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHN’S DISEASE: 104-WEEK EXTENSION RESULTS FROM A PHASE 2 RANDOMIZED CONTROLLED TRIAL

IL-23: Many but different? (Posters)  et al.

SODIUM BUTYRATE SUPPLEMENTATION SIGNIFICANTLY IMPROVED CLINICAL OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CROHN’S DISEASE – RESULTS FROM A RANDOMISED PLACEBO-CONTROLLED STUDY
SODIUM BUTYRATE SUPPLEMENTATION SIGNIFICANTLY IMPROVED CLINICAL OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CROHN’S DISEASE – RESULTS FROM A RANDOMISED PLACEBO-CONTROLLED STUDY

IL-23: Many but different? (Posters)  et al.

CORTICOSTEROID-SPARING EFFECT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB MAINTENANCE THERAPY
CORTICOSTEROID-SPARING EFFECT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB MAINTENANCE THERAPY

IL-23: Many but different? (Posters)  et al.

CORRELATION OF MIR-124 UPREGULATION AND PK PARAMETERS IN BLOOD OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS RECEIVING OBEFAZIMOD FOR 16 WEEKS
CORRELATION OF MIR-124 UPREGULATION AND PK PARAMETERS IN BLOOD OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS RECEIVING OBEFAZIMOD FOR 16 WEEKS

IL-23: Many but different? (Posters)  et al.

SHOULD ALL PATIENTS WITH NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASES BE SCREENED FOR METABOLIC BONE DISEASE? RESULTS FROM A DANISH POPULATION-BASED INCEPTION COHORT STUDY
SHOULD ALL PATIENTS WITH NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASES BE SCREENED FOR METABOLIC BONE DISEASE? RESULTS FROM A DANISH POPULATION-BASED INCEPTION COHORT STUDY

PHARMACOKINETICS, EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PAEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY
PHARMACOKINETICS, EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PAEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY

CORTICOSTEROID-SPARING EFFECT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB MAINTENANCE THERAPY
CORTICOSTEROID-SPARING EFFECT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB MAINTENANCE THERAPY

CORRELATION OF MIR-124 UPREGULATION AND PK PARAMETERS IN BLOOD OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS RECEIVING OBEFAZIMOD FOR 16 WEEKS
CORRELATION OF MIR-124 UPREGULATION AND PK PARAMETERS IN BLOOD OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS RECEIVING OBEFAZIMOD FOR 16 WEEKS

GUSELKUMAB, AN IL-23P19 SUBUNIT–SPECIFIC MONOCLONAL ANTIBODY, BINDS CD64 ON THE SURFACE OF IL-23-SECRETING MYELOID CELLS, CAPTURES LOCALLY PRODUCED IL-23, AND DELIVERS IL-23 TO INTRACELLULAR COMPARTMENTS
GUSELKUMAB, AN IL-23P19 SUBUNIT–SPECIFIC MONOCLONAL ANTIBODY, BINDS CD64 ON THE SURFACE OF IL-23-SECRETING MYELOID CELLS, CAPTURES LOCALLY PRODUCED IL-23, AND DELIVERS IL-23 TO INTRACELLULAR COMPARTMENTS

AZD7798: A NEW CCR9 DEPLETING ANTIBODY TO TREAT CROHN’S DISEASE
AZD7798: A NEW CCR9 DEPLETING ANTIBODY TO TREAT CROHN’S DISEASE

EARLY SYMPTOMATIC IMPROVEMENT WITH GUSELKUMAB INDUCTION TREATMENT IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
EARLY SYMPTOMATIC IMPROVEMENT WITH GUSELKUMAB INDUCTION TREATMENT IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY

EFFECT OF 104 WEEKS OF MIRIKIZUMAB TREATMENT ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
EFFECT OF 104 WEEKS OF MIRIKIZUMAB TREATMENT ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHN’S DISEASE: 104-WEEK EXTENSION RESULTS FROM A PHASE 2 RANDOMIZED CONTROLLED TRIAL
EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHN’S DISEASE: 104-WEEK EXTENSION RESULTS FROM A PHASE 2 RANDOMIZED CONTROLLED TRIAL

SODIUM BUTYRATE SUPPLEMENTATION SIGNIFICANTLY IMPROVED CLINICAL OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CROHN’S DISEASE – RESULTS FROM A RANDOMISED PLACEBO-CONTROLLED STUDY
SODIUM BUTYRATE SUPPLEMENTATION SIGNIFICANTLY IMPROVED CLINICAL OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CROHN’S DISEASE – RESULTS FROM A RANDOMISED PLACEBO-CONTROLLED STUDY

Item 1 - 20 / 20
1